Impact of kidney function on 200 days of antiviral prophylaxis for cytomegalovirus disease in CMV-seronegative recipients of CMV-seropositive donor kidneys Post hoc analysis of a randomized, phase 3 trial of letermovir versus valganciclovir prophylaxis.

acyclovir - Generic mfg.

Valcyte (valganciclovir) - Roche, Mitsubishi Tanabe

Prevymis (letermovir) - Merck (MSD)

http://www.ncbi.nlm.nih.gov/pubmed/40701254

Barbara Haber; Catherine B Small; Christopher L Gilbert; Klemens Budde; Marta Crespo; Nassim Kamar; Natalya Broyde; Nicole Stauffer; Pamela Moise

Jul 24, 2025